Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.

Inclusion Criteria:

• Meet the diagnostic criteria for AD-derived MCI or early AD [Clinical rating: CDR 0.5 (MCI) / 1.0 (mild AD), i.e., clinical stage 3-5; PIB-PET positive for pathology]
• Male or female
• 50-85 years old
• Not currently participating in other research studies
• Volunteers must provide written informed consent prior to study participation and voluntarily sign the informed consent form
• Volunteers are able to communicate effectively with investigators and comply with study procedures to complete the study

Exclusion Criteria:

• Other neurological disorders: e.g., vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration, prion diseases, etc.
• Systemic diseases or metabolic disorders: e.g., hypothyroidism, vitamin B12 deficiency, hepatic and renal failure.
• Infectious diseases: e.g., neurosyphilis, HIV-associated encephalopathy, and other infectious diseases.
• Psychiatric disorders: cognitive symptoms caused by severe depression (pseudodementia), schizophrenia, etc.
• Effects of drugs/toxins: long-term use of benzodiazepines, anticholinergic drugs, or alcohol dependence.